Author

T. Boch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Approach:benchmark study· 1 Research Focus:benchmarking· 1

Frequent Co-Authors

A. Trumpp· 3 shared D. Huebschmann· 3 shared D. Vonficht· 3 shared S. Haas· 3 shared L. Jopp-Saile· 2 shared R. Lutz· 2 shared S. Raffel· 2 shared A. Narr· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Trumpp

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia

M. Hartmann, M. Schoenung, J. Rajak, V. Maurer, L. Hai, K. Bauer, M. Hakobyan, S. Staeble, J. Langstein, L. Jardine, R. Roelz, S. Bohler, E. Khabirova, A.-H. Maag, D. Vonficht, , D. B. Lipka

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

bioRxiv · Oct 27, 2023Cancer Biology

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

R. Lutz, F. Gruenschlaeger, M. Simon, M. Bauer, S. Yousefian, N. Beumer, L. Jopp-Saile, M. Awwad, G. Steinbuss, A. Sedlmeier, T. Boch, D. Vonficht, M.-A. Baertsch, B. Durie, N. Weinhold, , S. Haas

This study examines immune changes in multiple myeloma survivors years after treatment, finding sustained immune alterations linked to residual disease and therapy.

bioRxiv · May 27, 2023 · PreprintCancer Biology

Comparison of extraction methods for intracellular metabolomics

C. Andresen, T. Boch, H. M. Gegner, N. Mechtel, A. Narr, E. Birgin, E. Rasbach, N. N. Rahbari, A. Trumpp, G. Poschet, D. Huebschmann

The paper compares ten metabolomics extraction protocols across four human sample types to identify the most effective method for quantifying 630 metabolites.

bioRxiv · Dec 15, 2021 · PreprintBiochemistry

Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states

S. H. Triana, D. Vonficht, L. Jopp-Saile, S. Raffel, R. Lutz, D. R. Leonce, M. Antes, P. Hernandez-Malmierca, D. Ordonez-Rueda, B. Ramasz, T. Boch, J.-C. Jann, D. Nowak, W.-K. Hofmann, C. Muller-Tidow, , S. Haas

The paper generates single-cell proteo-genomic reference maps of human hematopoietic cells to enable precise cell state purification and functional profiling.

bioRxiv · Mar 18, 2021Immunology